Phenethyl isothiocyanate and dasatinib combination synergistically reduces hepatocellular carcinoma growth via cell cycle arrest and oxeiptosis

• Egile Nagusiak: Gabriele Strusi (Egilea), Caterina M. Suelzu (Egilea), Nicole Horwood (Egilea), Andrea E. Münsterberg (Egilea), Yongping Bao (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2023-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Introduction: Hepatocellular carcinoma (HCC) is the most common type of liver cancer, which is among the most lethal tumours. Combination therapy exploits multiple drugs to target key pathways synergistically to reduce tumour growth. Isothiocyanates have been shown to possess anticancer potential an...